Want to see MYGN full AI Analyst Report?
MYGN Stock Chart & Stats
$5.08
$0.24(1.68%)
At close: 4:00 PM EST
$5.08
$0.24(1.68%)
Day’s Range― - ―
52-Week Range$3.53 - $8.59
Previous CloseN/A
Volume154.82K
Average Volume (3M)1.44M
Market Cap
$584.63M
Enterprise Value$508.75
Total Cash (Recent Filing)$124.40M
Total Debt (Recent Filing)$211.50M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Jul 30, 2026EPS Estimate
-0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.30
Shares Outstanding94,448,210
10 Day Avg. Volume949,599
30 Day Avg. Volume1,444,583
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.56
Price to Sales (P/S)0.70
P/FCF Ratio-22.41
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.80Price Target Upside33.86% Upside
Rating ConsensusHold
Number of Analyst Covering6
EPS Forecast (FY)0.06
Revenue Forecast (FY)$863.56M
Bulls Say, Bears Say
Bulls Say
High & Stable Gross MarginsSustained ~69% gross margins provide a durable structural advantage in molecular diagnostics, enabling funding of R&D and commercial expansion without immediate margin pressure. High gross margins support eventual operating leverage as revenues scale and help protect adjusted EBITDA targets against volume fluctuations.
Revenue Re-acceleration & Hereditary GrowthA strong revenue re-acceleration and double-digit hereditary testing volume growth indicate durable demand and market-share gains in core markets. Recurring clinician ordering and penetration into both affected and unaffected populations create a structurally larger and stickier revenue base over the medium term.
Deep Product Pipeline & Commercial InvestmentA multi-product launch roadmap (MRD, Prolaris+AI, FirstGene) plus material commercial investment and healthy capital runway are structural growth enablers. If launches achieve clinical and payer adoption, they expand addressable markets and diversify revenue beyond hereditary testing, supporting durable top-line expansion.
Bears Say
Persistent Losses & Negative Free Cash FlowLarge, persistent losses and negative free cash flow erode equity and constrain strategic flexibility. Reliance on balance-sheet capacity raises dilution or refinancing risk, limits discretionary spending, and means profitable scale must be achieved to sustain operations without recurring external funding.
Elevated Opex From Commercial Ramp; Timing RiskSubstantial upfront commercial hiring and higher opex create a timing mismatch: expenses accrue before new hires reach productivity. This execution timing risk can delay forecasted back-half revenue gains, pressuring adjusted EBITDA and requiring sustained capital if ramp underperforms expectations.
Prenatal Business Weakness & Operational DisruptionA notable prenatal revenue decline and lost accounts from system disruption indicate operational and retention weaknesses. Weakness in this business reduces revenue diversification, undermines short-to-medium-term stability, and signals execution gaps that must be fixed to restore provider confidence and volumes.
Myriad Genetics News
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $3.53 and its highest was $8.59 in the past 12 months.
What is Myriad Genetics’s market cap?
Myriad Genetics’s market cap is $584.63M.
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Jul 30, 2026 which is in 12 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on May 05, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.068 by -$0.022.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Monthly dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is -0.06.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 94,448,210 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.068. Following the earnings report the stock price went down -18.29%.
Which hedge fund is a major shareholder of Myriad Genetics?
Currently, no hedge funds are holding shares in MYGN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Myriad Genetics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.80 (33.86% Upside)
$6.80 (33.86% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 453.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $27.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
22.33%
12-Months-Change
Fundamentals
Return on Equity
-109.09%
Trailing 12-Months
Asset Growth
-33.04%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc., a molecular diagnostics and precision medicine company, develops molecular tests. The company offers molecular diagnostic tests for oncology, women’s health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; FirstGene; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; University of Texas M.D. Anderson Cancer Center; Mayo Foundation for Medical Education and Research; Children’s Medical Center in Boston; Institut Curie and INSERM; and Eurobio Scientific SA. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
MYGN Stock 12 Month Forecast
Average Price Target
$6.80
▲(33.86% Upside)
Technical Analysis
Ownership Overview
6.19% Insiders
15.98% Mutual Funds
1.13% Other Institutional Investors
59.38% Public Companies and
Individual Investors